SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A,Siegel R,Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
  • 2
    Ries LAG,Eisner MP. Cancer of the lung. In: RiesLAG, YoungJL, KeelGE, EisnerMP, LinYD, HornerM-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. NIH Pub. No. 07-6215. Bethesda, Md: National Cancer Institute, SEER Program; 2007: 76.
  • 3
    National Cancer Institute, U.S. National Institutes of Health website on small-cell lung cancer for health professionals. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional/page2 Accessed on April 8, 2009.
  • 4
    Fry WA,Menck HR,Winchester DP. The National Cancer Data Base report on lung cancer. Cancer. 1996; 77: 1947-1955.
  • 5
    Johnson BE,Grayson J,Makuch RW, et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol. 1990; 8: 396-401.
  • 6
    Lassen U,Osterlind K,Hansen M,Dombernowsky P,Bergman B,Hansen HH. Long-term survival in small-cell lung cancer: post-treatment characteristics in patients surviving 5 to ≥18 years—an analysis of 1,714 consecutive patients. J Clin Oncol. 1995; 13: 1215-1220.
  • 7
    Johnson BE,Bridges JD,Sobczeck M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996; 14: 806-813.
  • 8
    Murray N,Coy P,Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993; 11: 336-344.
  • 9
    Turrisi AT,3rd,Kim K,Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340: 265-271.
  • 10
    Albain KS,Crowley JJ,LeBlanc M,Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580-patient Southwest Oncology Group data base. J Clin Oncol. 1990; 8: 1563-1574.
  • 11
    Cerny T,Blair V,Anderson H,Bramwell V,Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987; 39: 146-149.
  • 12
    Rawson NS,Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Res. Br J Cancer. 1990; 61: 597-604.
  • 13
    Sculier JP,Chansky K,Crowley JJ,Van Meerbeeck J,Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol. 2008; 3: 457-466.
  • 14
    Souhami RL,Bradbury I,Geddes DM,Spiro SG,Harper PG,Tobias JS. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 1985; 45: 2878-2882.
  • 15
    Wolf M,Holle R,Hans K,Drings P,Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer. 1991; 63: 986-992.
  • 16
    Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-202.
  • 17
    Mandrekar SJ,Schild SE,Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006; 107: 781-792.
  • 18
    Grambsh PM,Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515-526.
  • 19
    Harrell FEJr,Lee KL,Califf RM,Pryor DB,Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984; 3: 143-152.
  • 20
    Auperin A,Arriagada R,Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999; 341: 476-484.
  • 21
    Slotman B,Faivre-Finn C,Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357: 664-672.
  • 22
    Jeremic B,Shibamoto Y,Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999; 17: 2092-2099.
  • 23
    Pignon JP,Arriagada R,Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327: 1618-1624.
  • 24
    Warde P,Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992; 10: 890-895.
  • 25
    Maksymiuk AW,Jett JR,Earle JD, et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol. 1994; 12: 70-76.
  • 26
    Frytak S,Shaw EG,Jett JR, et al. Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer. Am J Clin Oncol. 1996; 19: 193-198.
  • 27
    Rowland KMJrJr,Loprinzi CL,Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996; 14: 135-141.
  • 28
    Kirschling RJ,Grill JP,Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol. 1999; 22: 517-522.
  • 29
    Marschke RFJr,Grill JP,Sloan JA, et al. Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. Am J Clin Oncol. 1999; 22: 15-17.
  • 30
    Schaefer PL,Marks RS,Mahoney MR, et al. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. Am J Clin Oncol. 2003; 26: 236-240.
  • 31
    Perez EA,Geoffroy FJ,Hillman S, et al. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer. 2004; 44: 347-353.
  • 32
    Jett JR,Hatfield AK,Hillman S, et al. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Cancer. 2003; 97: 2498-2503.
  • 33
    Molina JR,Jett JR,Foster N, et al. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol. 2006; 29: 246-251.
  • 34
    Bonner JA,Sloan JA,Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999; 17: 2681-2691.
  • 35
    Schild SE,Bonner JA,Hillman S, et al. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol. 2007; 25: 3124-3129.
  • 36
    Garces YI,Okuno SH,Schild SE, et al. Phase I North Central Cancer Treatment Group Trial N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 995-1001.